title: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
abstract: BACKGROUND
  KRAS mutation status is a candidate marker for predicting survival in patients with metastatic colorectal cancer (mCRC) treated with cetuximab (CTX).
  
  
  METHODS
  We studied the KRAS mutation status of 113 patients with irinotecan refractory mCRC treated with CTX in clinical trials. A predictive model for objective response (OR), progression-free survival (PFS) and overall survival (OS) was constructed using logistic and Cox regression.
  
  
  RESULTS
  OR was seen in 27 of 66 KRAS wild-type (WT) patients versus 0 of 42 in KRAS mutants. Median OS was significantly better in KRAS WT versus mutants (43.0 versus 27.3 weeks; P = 0.020). Decrease in tumor sizes was significantly larger at all time points in WT patients. KRAS WT patients with an initial relative decrease of tumor size >9.66% at week 6 had a significantly better median OS compared with all other patients (74.9 versus 30.6 weeks; P = 0.0000025). Within KRAS WT patients OS was significantly better in patients with an initial decrease compared with those without [median OS: 74.9 versus 30.6 weeks (P = 0.00000012)].
  
  
  CONCLUSIONS
  KRAS WT status is associated to survival benefit in CTX treated mCRC. This benefit is even more pronounced in those patients with early radiological response. These characteristics may be exploited for response prediction.
authors.affiliation: Center for Human Genetics, Katholieke Universiteit Leuven, Leuven, Belgium.
authors.forename: W
authors.initials: W
authors.lastname: De Roock
authors.forename: H
authors.initials: H
authors.lastname: Piessevaux
authors.forename: J
authors.initials: J
authors.lastname: De Schutter
authors.forename: M
authors.initials: M
authors.lastname: Janssens
authors.forename: G
authors.initials: G
authors.lastname: De Hertogh
authors.forename: N
authors.initials: N
authors.lastname: Personeni
authors.forename: B
authors.initials: B
authors.lastname: Biesmans
authors.forename: J-L
authors.initials: JL
authors.lastname: Van Laethem
authors.forename: M
authors.initials: M
authors.lastname: Peeters
authors.forename: Y
authors.initials: Y
authors.lastname: Humblet
authors.forename: E
authors.initials: E
authors.lastname: Van Cutsem
authors.forename: S
authors.initials: S
authors.lastname: Tejpar
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D000077146:Irinotecan; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016016:Proportional Hazards Models; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D016283:Proto-Oncogene Proteins p21(ras); D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D015996:Survival Rate; D014057:Tomography, X-Ray Computed; D018631:ras Proteins / Q000032:analysis*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077146:Irinotecan; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab; D002166:Camptothecin